Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
Titel:
Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
Auteur:
Chaft, Jamie E. Litvak, Anya Arcila, Maria E. Patel, Payal D'Angelo, Sandra P. Krug, Lee M. Rusch, Valerie Mattson, Alicia Coeshott, Claire Park, Bernard Apelian, David M. Kris, Mark G. Azzoli, Christopher G.